Reviewed by Marcus Chen Updated February 20, 2026

Does Humana Cover Semaglutide? Insurance Guide 2026

Navigating insurance coverage for semaglutide can feel overwhelming, but understanding Humana’s policies is the first step toward accessing this transformative medication. Whether prescribed for type 2 diabetes or chronic weight management, semaglutide—sold under brand names like Ozempic® and Wegovy®—has revolutionized treatment for millions. This guide breaks down Humana’s coverage criteria, costs, and strategies to secure approval for semaglutide in 2026.

Does Humana Cover Semaglutide for Diabetes?

Humana’s coverage for semaglutide in the treatment of type 2 diabetes is generally consistent with clinical guidelines and FDA approvals. As of 2026, Humana’s pharmacy benefit plans typically cover semaglutide (Ozempic®) for patients with type 2 diabetes who meet specific criteria. These criteria often include a documented diagnosis of type 2 diabetes, prior failure or intolerance to first-line therapies like metformin, and a hemoglobin A1c (HbA1c) level above target (usually ≥7.0% or ≥8.0%, depending on the plan).

Humana’s coverage aligns with recommendations from the American Diabetes Association (ADA), which endorses semaglutide as a second-line therapy for patients who do not achieve glycemic control with metformin alone. The medication’s mechanism of action—enhancing glucose-dependent insulin secretion, suppressing glucagon, and slowing gastric emptying—makes it a powerful tool for improving glycemic control and reducing cardiovascular risk. However, Humana may require prior authorization to ensure semaglutide is prescribed appropriately and cost-effectively.

Patients should review their specific Humana plan details, as coverage can vary between Medicare Advantage, commercial, and employer-sponsored plans. Some plans may limit semaglutide to certain dosage strengths or require step therapy, where patients must try and fail other GLP-1 receptor agonists (e.g., liraglutide or dulaglutide) before gaining access to semaglutide.

Does Humana Cover Semaglutide for Weight Loss?

Humana’s coverage of semaglutide for chronic weight management is more restrictive than its coverage for diabetes. As of 2026, Humana typically covers semaglutide (Wegovy®) for weight loss only under specific conditions, reflecting its FDA approval for this indication. To qualify, patients must have a body mass index (BMI) of ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. Additionally, Humana often requires documentation of prior participation in a structured weight-loss program (e.g., diet, exercise, or behavioral therapy) for at least 6 months without achieving clinically meaningful weight loss.

The evidence supporting semaglutide for weight loss is robust. In the STEP clinical trials, semaglutide at a dose of 2.4 mg weekly led to an average weight loss of 15-20% over 68 weeks, far surpassing the 5-10% typically achieved with lifestyle interventions alone. Despite this, Humana may classify semaglutide as a “non-preferred” or “prior authorization required” medication for weight loss, given its high cost and the availability of alternative weight-loss therapies.

Patients should be prepared to provide detailed medical records, including BMI history, failed weight-loss attempts, and documentation of comorbidities. Some Humana plans may exclude coverage for weight-loss medications entirely, particularly in Medicare Advantage plans, where semaglutide for weight loss is often not covered under Part D. In such cases, patients may need to explore alternative options or pay out-of-pocket.

How Much Does Semaglutide Cost With Humana?

The cost of semaglutide with Humana insurance depends on several factors, including the specific plan, formulary tier, and whether the prescription is for diabetes or weight loss. Without insurance, semaglutide can cost upwards of $1,000 to $1,500 per month, but Humana’s coverage can significantly reduce this burden for eligible patients.

For diabetes management (Ozempic®), semaglutide is often placed on a preferred or non-preferred tier in Humana’s formulary. Patients with a standard commercial plan may face a copay of $30 to $100 per month, depending on the tier. Those with high-deductible plans may need to pay the full negotiated price (typically $800 to $1,200) until their deductible is met. Medicare Advantage plans may offer semaglutide at a lower copay, often $47 to $100 per month, but this varies by plan.

For weight loss (Wegovy®), the cost-sharing structure is less favorable. Semaglutide for weight loss is frequently placed on a higher formulary tier, resulting in copays of $100 to $300 per month or coinsurance of 30-50%. Some Humana plans may not cover Wegovy® at all, leaving patients to pay the full retail price. Additionally, Humana may impose quantity limits, such as a 30-day supply, to control costs.

Patients can reduce out-of-pocket expenses by using manufacturer savings programs. Novo Nordisk, the maker of semaglutide, offers copay cards that can lower costs to as little as $25 per month for eligible patients. However, these programs are typically not available to Medicare beneficiaries due to federal regulations.

Semaglutide Prior Authorization for Humana

Prior authorization is a common requirement for semaglutide under Humana’s pharmacy benefit, designed to ensure the medication is used appropriately and cost-effectively. For both diabetes and weight-loss indications, Humana’s prior authorization process typically involves several key steps.

For semaglutide (Ozempic®) in diabetes, Humana’s prior authorization criteria often include:

A confirmed diagnosis of type 2 diabetes.
Documentation of an HbA1c level above the target range (e.g., ≥7.0% or ≥8.0%).
Evidence of prior failure or intolerance to first-line therapies, such as metformin, sulfonylureas, or other GLP-1 receptor agonists.
For higher doses (e.g., 1.0 mg or 2.0 mg), proof of inadequate glycemic control on lower doses.

For semaglutide (Wegovy®) in weight loss, Humana’s criteria are more stringent and may include:

A BMI of ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity.
Documentation of participation in a structured weight-loss program for at least 6 months without achieving clinically meaningful weight loss.
Evidence of failed trials with other weight-loss medications (e.g., phentermine, orlistat, or liraglutide).
A signed attestation from the prescriber confirming the patient’s commitment to lifestyle modifications.

The prior authorization process usually begins with the prescriber submitting a request through Humana’s online portal or via fax. Humana’s pharmacy benefit manager (PBM) reviews the request within 3-5 business days, though expedited reviews may be available for urgent cases. If approved, the authorization is typically valid for 6-12 months, after which a renewal request may be required.

How to Get Humana to Cover Semaglutide

Securing Humana’s coverage for semaglutide requires a strategic approach, particularly for weight-loss indications where approval is less straightforward. Here are evidence-based steps to improve the likelihood of approval:

Ensure Medical Necessity: Humana’s coverage decisions hinge on medical necessity. For diabetes, this means providing lab results (e.g., HbA1c), records of failed therapies, and a clear rationale for why semaglutide is the best option. For weight loss, document BMI, comorbidities (e.g., hypertension, sleep apnea), and failed weight-loss attempts.
Complete Prior Authorization Thoroughly: Work with your prescriber to submit a detailed prior authorization request. Include all required documentation, such as lab results, progress notes, and attestations. Incomplete requests are a common reason for denial.
Leverage Clinical Guidelines: Cite evidence from clinical guidelines, such as the ADA Standards of Care for diabetes or the Obesity Medicine Association’s guidelines for weight loss. Highlight semaglutide’s proven benefits, such as improved glycemic control, reduced cardiovascular risk, and significant weight loss.
Appeal Step Therapy Requirements: If Humana requires step therapy (e.g., trying liraglutide before semaglutide), request an exception if you have a documented intolerance or contraindication to the required medication. Provide evidence, such as allergic reactions or severe side effects.
Use Manufacturer Support: Novo Nordisk offers resources to help patients navigate insurance coverage, including sample prior authorization letters and appeals assistance. Their website also provides a coverage tool to check Humana’s specific requirements.
Consider a Letter of Medical Necessity: A well-written letter from your prescriber can strengthen your case. The letter should outline your medical history, failed treatments, and why semaglutide is critical for your health. Include data from clinical trials to support its efficacy.
Explore Patient Assistance Programs: If Humana denies coverage, Novo Nordisk’s patient assistance program may provide semaglutide at a reduced cost or for free to eligible patients. These programs typically have income requirements.

What to Do If Humana Denies Semaglutide

A denial from Humana for semaglutide coverage can be frustrating, but it is not the end of the road. Here’s how to navigate the appeals process effectively:

Understand the Reason for Denial: Humana’s denial letter will specify why semaglutide was not approved. Common reasons include incomplete documentation, failure to meet medical necessity criteria, or lack of prior authorization. Identify the exact issue to address it in your appeal.
Request an Internal Appeal: Humana is required to allow at least one internal appeal. Submit a written request within 60 days of the denial, including:
- A copy of the denial letter.
- Additional medical records or documentation not previously submitted.
- A letter from your prescriber explaining why semaglutide is medically necessary.
- Relevant clinical guidelines or trial data supporting semaglutide’s use.
Escalate to an External Review: If Humana upholds the denial, you can request an external review by an independent third party. This process is available for most commercial plans and is often free for patients. The external reviewer will evaluate whether Humana’s decision was reasonable based on medical evidence.
Involve Your Prescriber: A strong appeal often requires input from your healthcare provider. Ask your prescriber to write a detailed letter of medical necessity, including:
- Your diagnosis and treatment history.
- Why alternative therapies are inappropriate or ineffective.
- The potential consequences of not using semaglutide (e.g., worsening glycemic control, increased cardiovascular risk).
Consider Legal or Advocacy Support: If appeals are unsuccessful, organizations like the Patient Advocate Foundation or state insurance commissioners may offer assistance. For Medicare Advantage plans, you can request a reconsideration through the Centers for Medicare & Medicaid Services (CMS).
Explore Alternative Funding: If appeals fail, look into Novo Nordisk’s patient assistance program or copay cards. Some pharmacies also offer discount programs or payment plans for semaglutide.

Humana Alternatives If Semaglutide Is Not Covered

If Humana denies coverage for semaglutide, several alternatives may be available, depending on whether the prescription is for diabetes or weight loss. Here are evidence-based options to discuss with your healthcare provider:

For Diabetes:

Other GLP-1 Receptor Agonists: Humana may cover alternative GLP-1 agonists, such as:
- Liraglutide (Victoza®): A once-daily injectable with proven cardiovascular benefits. It is often preferred by Humana for patients with established cardiovascular disease.
- Dulaglutide (Trulicity®): A once-weekly injectable with a similar efficacy profile to semaglutide. It may be placed on a lower formulary tier, resulting in lower out-of-pocket costs.
- Exenatide (Byetta® or Bydureon®): A shorter-acting GLP-1 agonist that may be covered as a first-line option.
SGLT2 Inhibitors: Medications like empagliflozin (Jardiance®) or canagliflozin (Invokana®) improve glycemic control and reduce cardiovascular risk. They are often covered without prior authorization.
Insulin: For patients with advanced type 2 diabetes, Humana typically covers basal insulins (e.g., glargine or detemir) or premixed insulins. However, insulin may not address weight loss or cardiovascular benefits as effectively as semaglutide.

For Weight Loss:

Other GLP-1 Agonists: Humana may cover liraglutide (Saxenda®) for weight loss, which has a similar mechanism of action to semaglutide. While less effective than semaglutide, it can still produce clinically meaningful weight loss.
Phentermine/Topiramate (Qsymia®): This combination medication is FDA-approved for weight loss and may be covered by Humana. It is particularly effective for patients with obesity-related comorbidities.
**Naltrexone